Professor Mark Socinski joins us live from ASCO 2024 to share his views on the lung cancer data emerging from the conference.
In this short video update, he shares his insights on data from the LAURA and ADRIATIC trials and what they could mean for clinical practice in lung cancer management.
ASCO 2024 selected lung cancer abstracts
- Osimertinib after definitive chemoradiotherapy in patients with unresectable stage 3 EGFRm NSCLC: Primary results of the phase 3 LAURA study.
Ramalingam S, et al.
Abstract LBA4, ASCO 2024
- ADRIATIC: durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
Spigel D, et al.
Abstract LBA5, ASCO 2024